Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francois Ghiringhelli

Showing results (21-30 of 95) with videos related to

Pageof 10
Sort By:
World Journal of Gastroenterology|January 14, 2017
Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair proteinFrancois Ghiringhelli, Corentin Richard, Sandy Chevrier, et al.
Journal for Immunotherapy of Cancer|October 27, 2023
FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short reportNicolas Roussot, Julie Lecuelle, Lorraine Dalens, et al.
Journal of Cancer Research and Clinical Oncology|June 1, 2020
Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in FranceAnne Aarnink, Jean David Fumet, Laure Favier, et al.
Journal of Gastrointestinal Oncology|September 17, 2021
Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancerZoé Tharin, Julie Blanc, Ikram Charifi Alaoui, et al.
Cancer Immunology, Immunotherapy : CII|March 16, 2022
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancerMarion Thibaudin, Emeric Limagne, Léa Hampe, et al.
Molecular and Clinical Oncology|October 11, 2021
Utility of exome sequencing in routine care for metastatic colorectal cancerMelchior De Giraud D'Agay, Loïck Galland, Zoe Tharin, et al.
World Journal of Gastroenterology|March 4, 2014
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patientsLaurie Rambach, Aurelie Bertaut, Julie Vincent, et al.
World Journal of Gastroenterology|February 27, 2015
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinomaJean-Florian Guion-Dusserre, Veronique Lorgis, Julie Vincent, et al.
Anticancer Research|October 3, 2018
Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine TumorsThomas Collot, Jean-David Fumet, Quentin Klopfenstein, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Immunological features of coronavirus disease 2019 in patients with cancerMarion Thibaudin, Jean-David Fumet, Marjorie Bon, et al.
Pageof 10

Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
World Journal of Gastroenterology|January 14, 2017
Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair proteinFrancois Ghiringhelli, Corentin Richard, Sandy Chevrier, et al.
Journal for Immunotherapy of Cancer|October 27, 2023
FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short reportNicolas Roussot, Julie Lecuelle, Lorraine Dalens, et al.
Journal of Cancer Research and Clinical Oncology|June 1, 2020
Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in FranceAnne Aarnink, Jean David Fumet, Laure Favier, et al.
Journal of Gastrointestinal Oncology|September 17, 2021
Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancerZoé Tharin, Julie Blanc, Ikram Charifi Alaoui, et al.
Cancer Immunology, Immunotherapy : CII|March 16, 2022
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancerMarion Thibaudin, Emeric Limagne, Léa Hampe, et al.
Molecular and Clinical Oncology|October 11, 2021
Utility of exome sequencing in routine care for metastatic colorectal cancerMelchior De Giraud D'Agay, Loïck Galland, Zoe Tharin, et al.
World Journal of Gastroenterology|March 4, 2014
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patientsLaurie Rambach, Aurelie Bertaut, Julie Vincent, et al.
World Journal of Gastroenterology|February 27, 2015
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinomaJean-Florian Guion-Dusserre, Veronique Lorgis, Julie Vincent, et al.
Anticancer Research|October 3, 2018
Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine TumorsThomas Collot, Jean-David Fumet, Quentin Klopfenstein, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Immunological features of coronavirus disease 2019 in patients with cancerMarion Thibaudin, Jean-David Fumet, Marjorie Bon, et al.
Pageof 10